NextCure Inc reports results for the quarter ended June 30 - Earnings Summary

NextCure

06/08/2026 21:39

NextCure Inc NXTC.OQ reported a quarterly adjusted loss of $2.80​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-11.29.  The mean expectation of three analysts for the quarter was for a loss of $1.93 per share. Wall Street expected results to range from $-2.03 to $-1.84 per share.
Reported revenue was zero​; analysts expected zero. 
NextCure Inc's reported EPS for the quarter was a loss of $2.80​.
The company reported a quarterly loss of $14.89 million.
NextCure Inc shares had risen by 228.1% this quarter and lost 63.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 12.2% in the last three months.​ 
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for NextCure Inc is $17.50, about 70% above its last closing price of $5.25
This summary was machine generated from LSEG data August 6 at 08:39 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-1.93
-2.80
Missed
Mar. 31 2026 
-2.10
-1.87
Beat
Dec. 31 2025 
-2.42
-0.81
Beat
Sep. 30 2025 
-3.98
-3.22
Beat